47.51
price up icon0.12%   0.02
 
loading
前日終値:
$47.49
開ける:
$47.46
24時間の取引高:
967.33K
Relative Volume:
0.34
時価総額:
$114.77B
収益:
$49.41B
当期純損益:
$5.59B
株価収益率:
18.42
EPS:
2.5789
ネットキャッシュフロー:
$12.54B
1週間 パフォーマンス:
+1.08%
1か月 パフォーマンス:
-1.29%
6か月 パフォーマンス:
+2.96%
1年 パフォーマンス:
-10.07%
1日の値動き範囲:
Value
$47.35
$47.62
1週間の範囲:
Value
$47.20
$48.60
52週間の値動き範囲:
Value
$44.62
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
名前
Sanofi Adr
Name
セクター
Healthcare (1117)
Name
電話
-
Name
住所
-
Name
職員
82,878
Name
Twitter
@sanofi
Name
次回の収益日
2026-01-29
Name
最新のSEC提出書
Name
SNY's Discussions on Twitter

Compare SNY vs LLY, JNJ, ABBV, MRK, NVS

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
SNY
Sanofi Adr
47.52 114.70B 49.41B 5.59B 12.54B 2.5789
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,054.96 913.67B 65.18B 20.64B 6.44B 22.96
Drug Manufacturers - General icon
JNJ
Johnson Johnson
239.35 572.91B 94.19B 26.80B 20.46B 11.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
223.62 387.09B 61.16B 4.20B 19.68B 2.3671
Drug Manufacturers - General icon
MRK
Merck Co Inc
122.53 297.22B 65.00B 18.26B 13.05B 7.2751
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
155.15 293.76B 54.72B 14.02B 15.32B 7.1855

Sanofi Adr Stock (SNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-27 開始されました Citigroup Neutral
2026-01-16 ダウングレード UBS Buy → Neutral
2026-01-06 ダウングレード Barclays Overweight → Equal Weight
2025-12-09 ダウングレード Guggenheim Buy → Neutral
2025-12-08 ダウングレード JP Morgan Overweight → Neutral
2025-09-08 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-09-02 アップグレード Deutsche Bank Hold → Buy
2025-08-08 アップグレード JP Morgan Neutral → Overweight
2025-04-15 開始されました Exane BNP Paribas Outperform
2025-03-21 開始されました Goldman Neutral
2025-01-30 アップグレード Deutsche Bank Sell → Hold
2024-07-26 繰り返されました Argus Buy
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-05 ダウングレード JP Morgan Overweight → Neutral
2023-10-30 ダウングレード Stifel Buy → Hold
2023-09-06 アップグレード Berenberg Hold → Buy
2023-07-14 開始されました HSBC Securities Buy
2023-04-28 ダウングレード Deutsche Bank Hold → Sell
2023-03-27 アップグレード Barclays Equal Weight → Overweight
2022-12-13 再開されました Morgan Stanley Overweight
2022-08-12 アップグレード Deutsche Bank Sell → Hold
2022-08-09 ダウングレード UBS Buy → Neutral
2022-05-23 開始されました SVB Leerink Outperform
2021-09-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-01-15 開始されました Deutsche Bank Sell
2020-09-29 開始されました Berenberg Hold
2020-03-17 アップグレード Barclays Underweight → Equal Weight
2020-03-11 アップグレード Goldman Neutral → Buy
2020-02-11 開始されました SVB Leerink Mkt Perform
2020-01-06 アップグレード JP Morgan Neutral → Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-09-20 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-09-03 開始されました Bernstein Outperform
2019-08-14 アップグレード UBS Neutral → Buy
2018-12-11 アップグレード Jefferies Hold → Buy
2018-11-01 アップグレード Barclays Underweight → Equal Weight
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Neutral → Buy
2018-08-10 アップグレード Citigroup Neutral → Buy
2018-03-23 アップグレード Liberum Hold → Buy
2018-01-23 ダウングレード Barclays Equal Weight → Underweight
2017-12-06 ダウングレード BofA/Merrill Buy → Neutral
2017-12-01 ダウングレード Morgan Stanley Overweight → Underweight
2017-11-15 アップグレード Barclays Underweight → Equal Weight
2017-08-30 アップグレード HSBC Securities Reduce → Hold
すべてを表示

Sanofi Adr (SNY) 最新ニュース

pulisher
05:00 AM

Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.

05:00 AM
pulisher
Feb 03, 2026

Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz

Feb 03, 2026
pulisher
Feb 02, 2026

Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm

Feb 02, 2026
pulisher
Feb 02, 2026

FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Feb 02, 2026
pulisher
Feb 02, 2026

Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm

Feb 02, 2026
pulisher
Jan 30, 2026

REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz

Jan 30, 2026
pulisher
Jan 30, 2026

European ADRs Slip, But Still End The Week Higher - Finimize

Jan 30, 2026
pulisher
Jan 30, 2026

Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa

Jan 30, 2026
pulisher
Jan 29, 2026

SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka

Jan 29, 2026
pulisher
Jan 29, 2026

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com

Jan 29, 2026
pulisher
Jan 26, 2026

Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz

Jan 26, 2026
pulisher
Jan 26, 2026

Corticosteroids Market Report 2026 - GlobeNewswire Inc.

Jan 26, 2026
pulisher
Jan 21, 2026

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz

Jan 21, 2026
pulisher
Jan 18, 2026

The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS

Jan 18, 2026
pulisher
Jan 16, 2026

Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz

Jan 16, 2026
pulisher
Jan 16, 2026

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz

Jan 16, 2026
pulisher
Jan 15, 2026

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz

Jan 15, 2026
pulisher
Jan 13, 2026

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz

Jan 13, 2026
pulisher
Jan 12, 2026

Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz

Jan 12, 2026
pulisher
Jan 10, 2026

The Truth About Sanofi S.A.: Is This ‘Boring’ Pharma Stock a Secret Power Play? - AD HOC NEWS

Jan 10, 2026
pulisher
Jan 09, 2026

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail

Jan 09, 2026
pulisher
Jan 07, 2026

Regeneron Just Moved From Underperform To Buy - Benzinga

Jan 07, 2026
pulisher
Jan 05, 2026

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz

Jan 05, 2026
pulisher
Jan 02, 2026

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz

Jan 02, 2026
pulisher
Dec 31, 2025

Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm

Dec 31, 2025
pulisher
Dec 30, 2025

Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Where is Sanofi (SNY) Headed According to Wall Street? - Finviz

Dec 30, 2025
pulisher
Dec 29, 2025

Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz

Dec 29, 2025
pulisher
Dec 28, 2025

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz

Dec 28, 2025
pulisher
Dec 25, 2025

Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets

Dec 25, 2025
pulisher
Dec 24, 2025

Why Dynavax Stock Soared Today - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm

Dec 24, 2025
pulisher
Dec 24, 2025

Our Environmental Impact - Sanofi

Dec 24, 2025
pulisher
Dec 21, 2025

Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends

Dec 21, 2025
pulisher
Dec 17, 2025

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz

Dec 17, 2025

Sanofi Adr (SNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general PFE
$27.11
price up icon 2.30%
$150.25
price up icon 0.60%
$374.91
price up icon 1.77%
drug_manufacturers_general NVO
$46.72
price up icon 7.81%
drug_manufacturers_general AZN
$190.92
price up icon 1.91%
drug_manufacturers_general NVS
$155.26
price up icon 0.81%
大文字化:     |  ボリューム (24 時間):